Skip to main content

Vaccines
for the Future

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu of Scripps Research to develop and commercialize prophylactic vaccines for the most challenging infectious diseases